20 Jul Metcela
Posted at 20:51h
in
Sarah Johnson, Chief Business Officer
Oct. 5 | 11:15am | FLW Ballroom G
Kawasaki, Japan
(Private)
Metcela Inc. is a late clinical-stage biotechnology company advancing JRM-001, an autologous cardiac stem cell therapy currently in Phase 3 clinical trials in Japan for patients with single ventricle disorders and reduced ejection fraction. Clinical studies to date have demonstrated favorable safety, improvements in cardiac function, and reductions in adverse events. With commercial launch in Japan anticipated by 2030, Metcela is actively seeking strategic partners to support global expansion, including entry into the U.S. market.